PDCD1 and small cell lung carcinoma: According to our knowledge, this is the largest NMA of included studies evaluating the effectiveness and security of PD‐1 inhibitors plus chemotherapy and PD‐L1 inhibitors plus chemotherapy in the initial therapy of patients with ES‐SCLC.